A nurse is providing teaching to a client who is newly diagnosed with Alzheimer’s disease. Which of the following treatment options should the nurse include in the teaching?

Choice A reason: Hospice care applies to terminal stages (6 months or less), not a newly diagnosed Alzheimer’s client, who may live years. It’s end-of-life support, not a treatment to alter disease progression. This option is premature and irrelevant to early management, so it’s incorrect. Choice B reason: Transcranial magnetic stimulation treats depression, not Alzheimer’s cognitive decline directly. It stimulates brain activity but lacks evidence for improving memory or cognition in this disease. This experimental approach doesn’t fit standard care, making it an unsuitable teaching point. Choice C reason: Barbiturates sedate for seizures or anesthesia, not anxiety in Alzheimer’s, risking dependency and worsening cognition. Benzodiazepines are preferred if needed, but neither is a core treatment. This outdated, risky option doesn’t address the disease, so it’s not appropriate. Choice D reason: NMDA receptor agonists like memantine slow cognitive decline in Alzheimer’s by regulating glutamate, reducing excitotoxicity. This FDA-approved treatment delays memory loss, a key teaching point for new diagnoses. It aligns with disease management, making it the correct choice.